查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年獸用鎮痛藥物的全球市場
市場調查報告書
商品編碼
1166510

2022-2029 年獸用鎮痛藥物的全球市場

Global Veterinary Pain Management Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年獸用鎮痛藥物的全球市場規模預計將達到 12.217 億美元，在預測期內（2022-2029 年）以 5.6% 的複合年增長率增長。

獸醫疼痛管理是指為伴侶動物和農場動物提供骨關節炎、術後疼痛和癌症等疾病的預防、診斷和治療的醫療服務。

市場動態

全球獸醫疼痛管理市場的增長是由特定因素驅動的，例如動物疼痛和炎症性疾病患病率上升、動物保健力度加大以及伴侶動物數量增加等因素驅動。

政府對動物保健的舉措不斷增加，預計將在預測期內推動全球獸醫鎮痛藥物市場。

2019 年 11 月，世界小動物獸醫協會 (WSAVA) 的全球疼痛委員會 (GPC) 宣布，其目標是建立疼痛管理領域的關鍵意見領袖 (KOL) 全球網絡。我們啟動了一個名為“教學”並正在開展雄心勃勃的活動，以在該地區傳播和傳播知識。

2020 年 3 月，10% 酮芬的製造商 Seba Animal Health 發布了“向疼痛揮手告別”，強調了緩解疼痛對跛腳牛的積極影響及其在改善恢復時間和性能方面的作用。”推出了活動。 該運動揭示了注射非甾體抗炎藥（抗炎鎮痛藥）與有效修蹄和阻滯治療跛足的協同作用（不僅僅是相加）。它是根據研究結果發起的。 這一發現是第二項表明奶牛場經營者在過去十年中越來越意識到他們需要緩解疼痛的研究，其中 52% 願意支付額外費用（高於 2006 年的 36%）。與結果一起發布。

分銷渠道的變化可能會阻礙市場增長

伴侶動物主人通常直接從獸醫那裡購買獸藥。 伴侶動物主人已經改變了他們的購買模式，將他們的注意力轉移到基於互聯網的零售商、零售店和其他銷售點渠道。 當確定人類藥物更便宜時，此類變化導致伴侶健康所有者選擇人類藥物而不是動物藥物。

此外，獸醫等主要客戶的整合會對配套保健產品的定價產生負面影響。 此外，低價仿製藥及其增加的使用量可能會阻礙市場潛力。 監管機構的監管會對止痛藥的銷售產生不利影響。 伴隨醫療保健成本的上升和對動物試驗的嚴格監管可能會進一步阻礙市場。

此外，由於運輸網絡不完善、缺乏冷藏設施以及缺乏用於健康檢查的化驗實驗室網絡，可能難以將藥品和疫苗運送到需要的地方。 採購模式的變化、仿製藥使用的增加、低價人用藥物的次級限制以及監管限制是可能顯著抑制市場增長的一些關鍵因素。

COVID-19 影響分析

COVID-19 疫情正在影響全球所有行業，包括動物止痛藥。 建議寵物父母與寵物保持安全距離，以保持衛生並降低感染風險。 此外，畜牧業也受到影響。 肉類、牛奶和雞蛋等動物產品越來越難以銷售。 對反芻動物的季節性過境點實施了限制。 例如，2020 年 4 月，糧食及農業組織在 COVID-19 大流行期間宣布了有關畜牧生產和動物產品供應鏈的新政策。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物劃分的市場細分
  • 按給藥途徑細分的市場
  • 按動物分類的市場細分
  • 按應用劃分的市場細分
  • 按分銷渠道細分的市場
  • 按地區劃分的市場細分

第四章市場動態

  • 市場影響因素
  • 司機
    • 動物中疼痛和炎症性疾病的流行率增加
    • 動物保健倡議的增加
    • 伴侶動物數量增加
  • 約束因素
    • 與藥物有關的副作用
    • 分銷渠道的變化
  • 商機
  • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類型分類

  • 非甾體抗炎藥
    • 美洛昔康
    • 德拉昔布
    • 卡洛芬
    • 依托度酸
    • 非羅考昔
    • 其他
  • 阿片類藥物
    • 嗎啡
    • 可待因
    • 芬太尼
    • 丁丙諾啡
    • 其他
  • 局部麻醉劑
    • 利多卡因
    • 布比卡因
    • 甲□卡因
    • 其他
  • α2激動劑
    • 美托咪定
    • 甲苯塞秦
    • 羅米非丁
    • 其他
  • 緩解疾病的骨關節炎治療劑 (DMOAD)
    • 其他

第8章給藥途徑

  • 口語
  • 腸外
  • 局部管理

第9章動物

  • 伴侶動物
    • 狗
    • 貓
    • 馬
    • 其他動物（伴侶動物）
  • 牲畜
    • 奶牛
    • 豬
    • 其他畜產品

第 10 章應用

  • 術後疼痛
  • 關節痛
    • 骨關節炎
    • 肌肉骨骼疾病
  • 癌症
  • 其他

第 11 章分銷渠道

  • 獸醫醫院和診所
  • 零售藥房
  • 在線藥店

第12章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第13章競爭格局

  • 競爭場景
  • 製造商採用的主要策略
  • 市場分析/市場份額分析
  • 產品基準

第14章公司簡介

  • Dechra Pharmaceuticals
    • 公司簡介
    • 程序組合和描述
    • 主要亮點
    • 財務摘要
  • Zoetis
  • Elanco
  • Boehringer Ingelheim
  • Vetoquinol S.A.
  • Ceva Sante Animale S.A.
  • Bayer AG
  • Merck Animal Health
  • Norbrook Laboratories
  • Chanelle Pharma
  • Virbac
  • Assisi Animal Health

第15章 數據

簡介目錄
Product Code: DMVH539

Market Overview

The global veterinary pain management drugs market size was valued at US$ 1221.7 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Veterinary Pain Management Drugs refers to the medical services for the prevention, diagnosis, and treatment of diseases like Osteoarthritis, Postoperative pain, and Cancer in companion and livestock animals.

Market Dynamics

The global veterinary pain management drugs market growth is driven by the certain factors such as the rising prevalence of painful and inflammatory diseases in animals, increasing initiatives towards animal healthcare and increasing number of companion animal ownership.

The increasing government initiative towards animal healthcare, is expected to drive the global veterinary pain management drugs market during the forecast period

In November 2019, the Global Pain Council (GPC) of the World Small Animal Veterinary Association (WSAVA) has launched a program called 'Teach the Teachers,' which aims to create a global network of key opinion leaders (KOLs) - 'teachers' - in pain management, who are motivated to propagate and disseminate their knowledge within their regions.

In March 2020, Ceva Animal Health, the manufacturer of Ketofen 10%, has launched a 'Wave Goodbye to Pain' campaign to highlight the positive impact of pain relief on lame cattle and the role it can play in improving recovery time and results. The initiative was launched following a study by Nottingham University which revealed that NSAIDs (anti-inflammatory and pain-relieving injections) have a synergistic (greater than simply additive) effect when given alongside effective hoof trimming and blocking to treat lameness. The findings have emerged alongside a second study showing that over the last 10 years, farmers are increasingly aware of the need for pain relief and 52% are happy to pay the extra costs involved (up from 36% in 2006).

Changes in distribution channel are likely to hinder the market growth

Generally, companion animal owners purchase their animal health products directly from veterinarians. Companion animal owners has changed their purchase pattern and shifted the focus towards internet-based retailers, retail stores, or other over-the-counter distribution channels. This shift is leading the companion health owners to opt for substitute human health products for animal health products if human health products are deemed to be lower-cost alternatives.

Moreover, consolidation of primary customers such as veterinarians might adversely affect price of companion healthcare products. Further, low-cost generic product subtitles and their increased usage might hamper the market potential. Restrictions by regulatory bodies might have a negative impact on the sales of pain relief drugs. Increasing costs of companion healthcare and increasing regulations on animal testing might further hamper the market.

Moreover, lack of infrastructure may also make it difficult to transport medicines and vaccines to where they are required because of poor transport links, lack of refrigeration, and networks of laboratories for conducting health tests. Change in purchase patterns, increased generic drugs, low-cost human drug sublimities, and regulatory restriction are key factors which might restrain the market growth significantly.

COVID-19 Impact Analysis

The COVID-19 outbreak has impacted all global industries, including veterinary pain medicine. Pet parents are advised to keep a safe distance from their pets to maintain hygiene and reduce the risk of contamination. Moreover, the impact has been seen in the livestock sector. Moving animal products, such as meat, milk, and eggs, has been trouble moving to markets. The restriction has been implemented on the seasonal border crossing with ruminants. For example, in April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and the supply chain of livestock products during the COVID-19 pandemic.

Segment Analysis

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-steroidal anti-inflammatory drugs are one of the most commonly used and most effective drug in the treatment of pain due to arthritis or after surgery in dogs and cats. Rimadyl, Metacam, Dermaxx, Etogesic, among others comes under this class of drugs. NSAIDS act by inhibiting inflammatory substances called prostaglandins (PGEs), which cause pain, inflammation, and fever. Hence they are called 'anti-inflammatory' but their main purpose is pain control (inflammation is how pain starts). These drugs are readily available, relatively long-acting, and generally inexpensive. They can also be given at home after an animal has been released from the hospital. For these reasons, they have long been used for pain relief. Veterinarians may prescribe NSAIDs as one part of the total plan for pain relief, provided the animal does not have kidney, liver, blood clotting, or stomach problems.

However, some side effects can occur, with the most common being gastrointestinal (GI) disturbance (symptoms include vomiting, diarrhea, bloody or dark colored feces) from minor GI-ulcers. There is also risk of acute liver and/or kidney failure with all NSAIDs.

Geographical Analysis

North America region holds the largest market share of the global veterinary pain management drugs market

North America accounted for the largest share of the veterinary pain management market. Rise in the number of veterinarians across the world is believed spearhead current and future market growth of veterinary pain management drugs during the forecast period. For instance, according to the 2019-2020 National Pet Owners Survey, conducted by the American Pet Products Association (APPA), around 67% of the country's households, or about 84.9 million families, own a pet. In addition, highly developed and well-established animal healthcare facilities is further fueling the growth.

Rising collective efforts by key players to improve their product portfolio and to ensure high-quality standards are projected to boost the regional demand. For instance, in May 2017, Norbrook launched chewable Carprieve tablets for dogs in a probe to expand its product portfolio.

In 2020, the United States Food & Drug Administration approved Cronus Pharma Specialties' Carprofen Chewable Tablets (generic version of Rimadyl-Zoetis) for dogs. This nonsteroidal anti-inflammatory drug (NSAID) has been proven safe and effective in relieving pain and inflammation associated with osteoarthritis. Also, it helps control postoperative pain associated with soft tissue and orthopedic surgeries.

Competitive Landscape

The veterinary pain management drugs market is highly competitive and consists of a large number of players.

Some of the major players in the global veterinary pain management drugs market are Dechra Pharmaceuticals, Zoetis, Elanco, Boehringer Ingelheim, Vetoquinol S.A., Ceva Sante Animale S.A., Bayer AG, Merck Animal Health, Norbrook Laboratories, Chanelle Pharma, Virbac, among others. The key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence.

For instance, In April 2020, The UK Competition and Markets Authority or CMA Monday has launched a merger inquiry into Dechra Pharmaceuticals PLC's (DPH.L) anticipated acquisition of the Osurnia business of Elanco Animal Health Inc. (ELAN).

Key Companies to Watch

Zoetis Inc

Overview: Zoetis Inc. is a U.S. based animal health company involved in the production of medicine, vaccines, diagnostic products and other veterinary solutions. The company is considered as the global leader in veterinary vaccines market. The company is operating under three reportable segments - Livestock, Companion Animal and Contract manufacturing & human health. Zoetis's Livestock business is responsible for the development, production and distribution of vaccines, anti-infective, paraciticides and medicated feed additives.

Product Portfolio: SIMBADOL (buprenorphine injection) offers continuous 24-hour surgical pain control for cats - even through the night.

The global veterinary pain management drugs market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drugs
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Animal
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
    • 4.2.2. Increasing Initiatives towards Animal Healthcare
    • 4.2.3. Increasing number of companion animal ownership
  • 4.3. Restraints
    • 4.3.1. Side Effects Associated with Drugs
    • 4.3.2. Changes in Distribution Channel
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. NSAIDS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
    • 7.2.3. Meloxicam
    • 7.2.4. Deracoxib
    • 7.2.5. Carprofen
    • 7.2.6. Etodolac
    • 7.2.7. Firocoxib
    • 7.2.8. Others
  • 7.3. Opioids
    • 7.3.1. Morphine
    • 7.3.2. Codeine
    • 7.3.3. Fentanyl
    • 7.3.4. Buprenorphine
    • 7.3.5. Others
  • 7.4. Local Anesthetics
    • 7.4.1. Lidocaine
    • 7.4.2. Bupivacaine
    • 7.4.3. Mepivacaine
    • 7.4.4. Others
  • 7.5. Alpha-2 Agonists
    • 7.5.1. Medetomidine
    • 7.5.2. Xylazine
    • 7.5.3. Romifidine
    • 7.5.4. Others
  • 7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
    • 7.6.1. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Topical

9. By Animal

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
    • 9.1.2. Market Attractiveness Index, By Animal Segment
  • 9.2. Companion Animal*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
    • 9.2.3. Dogs
    • 9.2.4. Cats
    • 9.2.5. Horses
    • 9.2.6. Other Companion Animals
  • 9.3. Livestock
    • 9.3.1. Cattle
    • 9.3.2. Swine
    • 9.3.3. Other Livestock Animals

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 10.1.2. Market Attractiveness Index, By Application Segment
  • 10.2. Postoperative Pain*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 10.3. Joint Pain
    • 10.3.1. Osteoarthritis
    • 10.3.2. Musculoskeletal Disorders
  • 10.4. Cancer
  • 10.5. Other

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Veterinary Hospitals & Clinics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. The Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Key Strategies adopted by Manufacturers
  • 13.3. Market Positioning/Share Analysis
  • 13.4. Product Benchmarking

14. Company Profiles

  • 14.1. Dechra Pharmaceuticals*
    • 14.1.1. Company overview
    • 14.1.2. Procedure portfolio and description
    • 14.1.3. Key highlights
    • 14.1.4. Financial overview
  • 14.2. Zoetis
  • 14.3. Elanco
  • 14.4. Boehringer Ingelheim
  • 14.5. Vetoquinol S.A.
  • 14.6. Ceva Sante Animale S.A.
  • 14.7. Bayer AG
  • 14.8. Merck Animal Health
  • 14.9. Norbrook Laboratories
  • 14.10. Chanelle Pharma
  • 14.11. Virbac
  • 14.12. Assisi Animal Health

15. DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us